Stock Events

GH Research 

€6.75
0
+€0+0% Friday 07:21

Statistics

Day High
6.75
Day Low
6.75
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
369.45M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-0.25
-0.16
-0.08
0.01
Expected EPS
-0.204
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1KA.F. It's not an investment recommendation.

About

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Show more...
CEO
Mr. Florian Schonharting M.Sc. (Econ)
Employees
32
Country
IE
ISIN
IE000GID8VI0
WKN
000A3CUAZ

Listings